IBJNews

Lilly shares get boost from OK of rival's drug

Back to TopCommentsE-mailPrintBookmark and Share

Shares of Eli Lilly and Co. and its partner Amylin Pharmaceuticals Inc. rose in pre-market trading on hopes that the companies’ new version of diabetes treatment Byetta will be approved following U.S. regulators’ clearance of a similar drug.

The U.S. Food and Drug Administration on Monday approved Victoza, a drug developed by Denmark-based Novo Nordisk A/S to compete against Byetta. Victoza is a once-daily shot, compared with the twice-daily Byetta.

But Indianapolis-based Lilly and San Diego-based Amylin have asked the FDA to approve a once-weekly version of Byetta, which would be the most convenient for patients. Analysts expect sales of once-weekly Byetta to reach as high as $2 billion by 2015, which would be split by Lilly and Amylin. Sales of twice-daily Byetta last year were on pace to reach about $790 million.

What’s been holding up Victoza and the once-weekly Byetta have been regulator concerns about patients developing inflammation of the pancreas while taking the drugs.

In approving Victoza, the FDA required its label to carry a warning about pancreatitis as well as a prohibition against use in patients at risk for a rare thyroid cancer after tumors developed in rodents.

Those warnings were milder than many analysts had feared.

“Given the fact that the FDA has clearly been agonizing over whether to approve this or not, it isn’t bad,” said Jack Scannell, an analyst at Sanford C. Bernstein Ltd. in London, who estimates Victoza could generate $900 million in annual sales by 2015.

Other analysts’ said the FDA’s decision on Victoza makes it likelier to approve once-weekly Byetta under the same terms.

“We continue to believe that Byetta LAR will receive the same treatment from the FDA” as Victoza, wrote analyst Joshua Schimmer of Leerink Swann, in a note to clients today.

Yaron Werber of Citigroup, wrote in a report to clients today, that the FDA is due to make a decision on once-weekly Byetta by March 5.

In morning trading, Amylin and Novo both saw their stock prices jump. Amylin shares rose as high as 14.5 percent and Novo shares surged as much as 4 percent. Lilly's stock price rose as much as 1 percent, to $36.14.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. If what you stated is true, then this article is entirely inaccurate. "State sells bonds" is same as "State borrows money". Supposedly the company will "pay for them". But since we are paying the company, we are still paying for this road with borrowed money, even though the state has $2 billion in the bank.

  2. Andrew hit the nail on the head. AMTRAK provides terrible service and that is why the state has found a contractor to improve the service. More trips, on-time performance, better times, cleanliness and adequate or better restrooms. WI-FI and food service will also be provided. Transit from outlying areas will also be provided. I wouldn't take it the way it is but with the above services and marketing of the service,ridership will improve and more folks will explore Indy and may even want to move here.

  3. They could take the property using eminent domain and save money by not paying the church or building a soccer field and a new driveway. Ctrwd has monthly meetings open to all customers of the district. The meetings are listed and if the customers really cared that much they would show. Ctrwd works hard in every way they can to make sure the customer is put first. Overflows damage the surrounding environment and cost a lot of money every year. There have been many upgrades done through the years to help not send flow to Carmel. Even with the upgrades ctrwd cannot always keep up. I understand how a storage tank could be an eye sore, but has anyone thought to look at other lift stations or storage tanks. Most lift stations are right in the middle of neighborhoods. Some close to schools and soccer fields, and some right in back yards, or at least next to a back yard. We all have to work together to come up with a proper solution. The proposed solution by ctrwd is the best one offered so far.

  4. Fox has comments from several people that seem to have some inside information. I would refer to their website. Changed my whole opionion of this story.

  5. This place is great! I'm piggy backing and saying the Cobb salad is great. But the ribs are awesome. $6.49 for ribs and 2 sides?! They're delicious. If you work downtown, head over there.

ADVERTISEMENT